Related Experiment Video

Updated: May 23, 2026

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language?

Chee Y Ooi1, Annie Dupuis, Lynda Ellis

  • 1School of Women's and Children's Health, Faculty of Medicine, University of New South Wales and Sydney Children's Hospital, Randwick, Sydney, Australia. keith.ooi@unsw.edu.au

Thorax
|April 17, 2012
PubMed

Insights

Despite differing cystic fibrosis (CF) guidelines, diagnostic concordance was good to excellent for patients with single organ issues. These findings support rigorous CF diagnosis without strict adherence to any single guideline.

Area of Science:

  • Medical diagnostics
  • Genetics and genomics
  • Pulmonology

Background:

  • Current cystic fibrosis (CF) diagnosis relies on varying American and European guidelines.
  • This discrepancy necessitates evaluating diagnostic concordance between these international recommendations.

Purpose of the Study:

  • To assess the diagnostic agreement between American and European cystic fibrosis guidelines.
  • To compare concordance across different CF phenotypes: chronic sinopulmonary disease (RESP), pancreatitis (PANC), and obstructive azoospermia (AZOOSP).

Main Methods:

  • Prospective evaluation of 208 subjects with single organ manifestations suggestive of CF.
  • Utilized sweat test, nasal potential difference measurements, and genotyping.
  • Measured diagnostic outcome concordance using observed agreement and kappa statistics.

Main Results:

  • Overall observed agreement was 84.8% (κ=0.87), indicating excellent concordance between guidelines.
  • The RESP phenotype showed the highest agreement (≥90%, κ=0.92), while PANC (86%, κ=0.65) and AZOOSP (80%, κ=0.87) showed good to excellent agreement.
  • Incorporating nasal potential difference into the American algorithm did not improve overall concordance and reduced it for AZOOSP.

Conclusions:

  • Concordance in diagnosing CF based on single organ manifestations is good to excellent despite guideline differences.
  • Existing guidelines promote rigorous CF evaluation, but should not be followed rigidly.
  • Extensive genotyping demonstrated limited clinical utility in CF diagnosis within these algorithms.
Abstract

More Related Videos

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD)09:47

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD)

Published on: September 13, 2018

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice08:55

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Published on: July 4, 2018

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Introduction to Language of Pathophysiology ll01:17

Introduction to Language of Pathophysiology ll

This lesson explores key terms that describe how diseases progress, their outcomes, and their distribution in populations.Diagnostic tests identify diseases and monitor treatment. These include blood and urine tests, biopsies, imaging (X-ray, MRI), and detection of infectious agents.Remission is a reduction or disappearance of symptoms.Exacerbation refers to the worsening of symptoms, such as increased wheezing during an asthma attack.A precipitating factor triggers an acute episode, while a...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Introduction to Language of Pathophysiology l01:25

Introduction to Language of Pathophysiology l

Pathophysiology investigates how biological mechanisms—typically starting at the cellular level—disrupt normal bodily functions. It bridges anatomy and physiology to explain the progression of disease. With this foundation, it is important to understand the following key terms used to describe disease processes: Diagnosis:The process of identifying a disease using clinical evaluation, including signs (objective evidence like rashes), symptoms (subjective experiences like pain), laboratory test...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...